4-氯-6-甲基喹啉-3-甲酸乙酯 | 56824-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-甲基喹啉-3-甲酸乙酯
• 中文别名: 4-氯-6-甲基-3-喹啉羧酸乙酯
• 英文名称: ethyl 4-chloro-6-methylquinoline-3-carboxylate
• CAS: 56824-87-4
• 化学式: C₁₃H₁₂ClNO₂
• mdl: MFCD00173357
• 分子量: 249.697
• InChiKey: GSIDXMVQPNWNIR-UHFFFAOYSA-N

物化性质

• 熔点：
  64-66℃
• 沸点：
  346.4±37.0 °C(Predicted)
• 密度：
  1.252

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Ethyl 4-Chloro-6-Methylquinoline-3-Carboxylate
: VBP00043
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Serious eye damage (Category 1), H318
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Causes serious eye damage.
Precautionary statement(s)
Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 249,7 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
Ethyl 4-Chloro-6-Methylquinoline-3-Carboxylate
Eye Dam. 1; H318 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
Ethyl 4-Chloro-6-Methylquinoline-3-Carboxylate
Xi, R41 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲基喹啉-3-甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 以74.4%的产率得到6-(溴甲基)-4-氯喹啉-3-羧酸乙酯
  参考文献：
  名称：

  取代的（喹啉羰基）胍衍生物的合成及其Na（+）/ H（+）交换子1的抑制活性。

  摘要：

  Na（+）/ H（+）交换子（NHE）是在许多哺乳动物细胞类型中表达的蛋白质。它通过将细胞外Na（+）交换为细胞内H（+）参与细胞内pH（pH（i））稳态。迄今为止，已鉴定出九种NHE亚型（NHE1-NHE9）。NHE1是哺乳动物心肌中最主要的同种型。设计并合成了一系列新的取代的（喹啉羰基）胍衍生物作为NHE抑制剂。大多数化合物可以浓度依赖性的方式抑制NHE1介导的血小板肿胀，其中化合物7f的活性最高，且比卡立哌利德更有效。此外，还已经证明化合物7f对SD大鼠心肌缺血-再灌注损伤表现出优于卡立泊来德的体内心脏保护作用。

  DOI：

  10.1002/cbdv.200800268
• 作为产物：
  描述：

  4-羟基-6-甲基喹啉-3-羧酸乙酯 在 三氯氧磷 作用下， 反应 0.33h， 以86%的产率得到4-氯-6-甲基喹啉-3-甲酸乙酯
  参考文献：
  名称：

  间日疟原虫 N-肉豆蔻酰转移酶抑制剂的发现：其结合模式的筛选、合成和结构表征

  摘要：

  N-肉豆蔻酰转移酶 (NMT) 是一种针对寄生原生动物的前瞻性药物靶点。在此，我们报告通过高通量筛选成功发现了一系列间日疟原虫NMT 抑制剂。获得了与 NMT 复合的命中化合物的高分辨率晶体结构，从而可以了解其新的结合模式。设计并测试了一组类似物以定义与活性和选择性相关的化学基团。

  DOI：

  10.1021/jm300040p

文献信息

• Quinoline derivatives having anti-tumor activity
  申请人：Imperial Chemical Industries PLC

  公开号：US05112837A1

  公开（公告）日：1992-05-12

  The invention relates to a quinoline of the formula: ##STR1## wherein each of R.sup.1 and R.sup.2, which may be the same or different, is hydrogen, halogeno, hydroxy, cyano, carbamoyl, nitro or amino, alkyl, alkoxy, alkylthio, alkylamino, dialkylamino or alkanoylamino each of up to 4 carbon atoms, or substituted alkyl or alkoxy each of up to 3 carbon atoms, provided that both R.sup.1 and R.sup.2 are not hydrogen; the quinoline ring may bear further substituents; R.sup.3 is hydrogen or alkyl of up to 4 carbon atoms; R.sup.4 is hydrogen, alkyl, alkenyl or alkynyl each of up to 4 carbon atoms or substituted alkyl of up to 3 carbon atoms; Ar is phenylene, naphthylene or heterocyclene which is unsubstituted or which bears one or more substituents; R.sup.5 is such that R.sup.5 --NH.sub.2 is an amino acid; or a pharmaceutically-acceptable salt or ester thereof. The compounds possess anti-tumor activity.

  本发明涉及一种喹啉，其公式为：##STR1## 其中，R.sup.1和R.sup.2可以是相同的或不同的，为氢、卤素、羟基、氰基、碳酰胺基、硝基或氨基，为碳原子数不超过4的烷基、烷氧基、烷硫基、烷氨基、二烷氨基或烷酮氨基，或为碳原子数不超过3的取代烷基或取代烷氧基，但R.sup.1和R.sup.2均不为氢；喹啉环可带有进一步的取代基；R.sup.3为氢或碳原子数不超过4的烷基；R.sup.4为氢、碳原子数不超过4的烷基、烯基或炔基，或为碳原子数不超过3的取代烷基；Ar为二价苯基、二价萘基或杂环基，其中未取代或带有1个或多个取代基；R.sup.5满足R.sup.5 --NH.sub.2是一种氨基酸；或其药用可接受的盐或酯。这些化合物具有抗肿瘤活性。
• A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease
  作者：Tarana Umar、Shruti Shalini、Md Kausar Raza、Siddharth Gusain、Jitendra Kumar、Prerna Seth、Manisha Tiwari、Nasimul Hoda

  DOI：10.1016/j.ejmech.2019.04.038

  日期：2019.8

  2-(piperazin-1-yl)N-(1H-pyrazolo[3,4-b]pyridin-3-yl)acetamides are described as a new class of selective and potent acetylcholinesterase (AChE) inhibitors and amyloid β aggregation inhibitors. Formation of synthesized compounds (P1P9) was justified via H1 NMR, C13 NMR, mass spectra and single crystal X-Ray diffraction study. All compounds were evaluated for their acetylcholinesterase and butyrylcholinesterase

  2-（哌嗪-1-基）N-（1H-吡唑并[3,4-b]吡啶-3-基）乙酰胺被描述为一类新型的选择性和有效的乙酰胆碱酯酶（AChE）抑制剂和淀粉样β聚集抑制剂。通过H 1 NMR，C 13 NMR，质谱和单晶X射线衍射研究证明了合成化合物（P1 P9）的形成。评价了所有化合物的乙酰胆碱酯酶和丁酰胆碱酯酶的抑制活性，自身介导的Aβ聚集的抑制和Cu（II）介导的Aβ聚集的抑制。而且，进行的对接研究与体外结果一致。衍生物中最有效的分子表现出出色的抗AChE活性（IC50  = 4.8 nM）。P3的动力学研究表明它是一种混合型抑制剂。体外研究表明，所有化合物均具有抑制自身诱导的β-淀粉样蛋白（Aβ）聚集的能力，最高抑制率为81.65％。的效力P1和P3抑制自诱导Aβ 1-42聚集通过TEM分析确定。还评估了化合物的Aβ分解，抗氧化，金属螯合活性。
• Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies
  作者：Jitendra Kumar、Poonam Meena、Anju Singh、Ehtesham Jameel、Mudasir Maqbool、Mohammad Mobashir、Ashutosh Shandilya、Manisha Tiwari、Nasimul Hoda、B. Jayaram

  DOI：10.1016/j.ejmech.2016.04.053

  日期：2016.8

  acetylcholinesterase inhibitors (AChEIs). Molecular docking and scoring was utilized for the design of inhibitors. The molecules were synthesized via an easily accessible, convergent synthetic route. Three triazolopyrimidine based compounds showed nanomolar activity towards acetylcholinesterase. Among them, Ethyl 6-fluoro-4-(4-(5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl)quinoline-3-carboxylate (10d)

  在本研究中，设计，合成和评估了一系列三唑并嘧啶-喹啉和氰基吡啶-喹啉杂化物，作为乙酰胆碱酯酶抑制剂（AChEI）。分子对接和评分用于抑制剂的设计。分子是通过容易获得的，会聚的合成途径合成的。三种基于三唑并嘧啶的化合物显示出对乙酰胆碱酯酶的纳摩尔活性。其中，乙基6-氟-4-（4-（5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-7-基）哌嗪-1-基）喹啉-3-羧酸酯（10d），强烈抑制AChE，IC 50值为42 nM。此外化合物10d被认为是对丁酰胆碱酯酶（BuChE）具有12倍选择性的最有前途的化合物。该化合物显示出组成的多目标概况，并有望抑制自身诱导的和AChE诱导的Aβ聚集以及抗氧化活性。
• Discovery of Plasmodium vivax<i>N</i>-Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding Mode
  作者：Victor Goncalves、James A. Brannigan、David Whalley、Keith H. Ansell、Barbara Saxty、Anthony A. Holder、Anthony J. Wilkinson、Edward W. Tate、Robin J. Leatherbarrow

  DOI：10.1021/jm300040p

  日期：2012.4.12

  N-Myristoyltransferase (NMT) is a prospective drug target against parasitic protozoa. Herein we report the successful discovery of a series of Plasmodium vivax NMT inhibitors by high-throughput screening. A high-resolution crystal structure of the hit compound in complex with NMT was obtained, allowing understanding of its novel binding mode. A set of analogues was designed and tested to define the

  N-肉豆蔻酰转移酶 (NMT) 是一种针对寄生原生动物的前瞻性药物靶点。在此，我们报告通过高通量筛选成功发现了一系列间日疟原虫NMT 抑制剂。获得了与 NMT 复合的命中化合物的高分辨率晶体结构，从而可以了解其新的结合模式。设计并测试了一组类似物以定义与活性和选择性相关的化学基团。
• Synthesis and anticancer activities of some novel 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones
  作者：Raísa da R. Reis、Elisa C. Azevedo、Maria Cecília B.V. de Souza、Vitor Francisco Ferreira、Raquel C. Montenegro、Ana Jérsia Araújo、Cláudia Pessoa、Letícia V. Costa-Lotufo、Manoel O. de Moraes、José D.B.M. Filho、Alessandra M.T. de Souza、Natasha C. de Carvalho、Helena C. Castro、Carlos R. Rodrigues、Thatyana R.A. Vasconcelos

  DOI：10.1016/j.ejmech.2011.01.066

  日期：2011.4

  A series of 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones (3a–g) have been synthesized and evaluated for their in vitro antiproliferative activities against four human cancer cell lines: MDA-MB-435 (breast), HL-60 (leukemia), HCT-8 (colon) and SF-295 (central nervous system). The results showed that the compounds 3b (2-(benzo[d]thiazol-2-yl)-8-methyl-2H-pyrazolo[4,3-

  合成了一系列的2-（苯并[ d ]噻唑-2-基）-8-取代的2 H-吡唑并[4,3 - c ]喹啉-3（5 H）-ones（3a – g），评估了它们对四种人类癌细胞系的体外抗增殖活性：MDA-MB-435（乳腺癌），HL-60（白血病），HCT-8（结肠）和SF-295（中枢神经系统）。结果显示化合物3b（2-（苯并[ d ]噻唑-2-基）-8-甲基-2 H-吡唑并[4,3 - c ]喹啉-3（5 H）-one）和3c（ 2-（苯并[ d ]噻唑-2-基）-8-溴-2 H-pyrazolo [4,3- c ] quinolin-3（5 H）-one）对三种细胞系均表现出良好的细胞毒性，IC 50值低于5μg/ mL。对理论毒性风险的分析表明，与阳性对照阿霉素相比，与3b和3c有关的中等致癌和刺激性风险。